About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.
Subscribe to this blog's feed

Contact the Docs

Recent Posts

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Patent Profile: MorphoSys Announces Issuance of Human Combinatorial Antibody Library (HuCAL) Patent | Main | An Analysis of the New Rules: 37 C.F.R. § 1.145: "Provoking" a Restriction Requirement »

October 03, 2007

Alethia Licenses Antibodies for Treating Cancer

    By Jason Derry --

Logo_alethia_francois Alethia Biotherapeutics Inc. has announced a licensing agreement with the National Research Council Biotechnology Research Institute (NRC-BRI).  Under the terms of the agreement, Alethia receives exclusive worldwide rights to a family of monoclonal antibodies that specifically block activity of secreted clusterin.  Alethia plans to move the anti-clusterin antibodies, which have demonstrated efficacy in animal models, into pre-clinical and clinical development.  NRC-BRI will provide access to its know-how in the fields of antibody humanization and therapeutic antibody development to assist Alethia in Institute_en_3 moving the antibodies through the clinical stage.  Alethia is a biotechnology company based in Montreal, and focuses on developing and discovering therapeutics for cancer and associated disorders.

Jason Derry, Ph.D., who graduated with honors from DePaul University College of Law, is a molecular biologist and founding author of Patent Docs.

Posted at 10:58 PM in Licensing |

Comments

The comments to this entry are closed.

May 2025

Sun Mon Tue Wed Thu Fri Sat
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

Categories

Archives

More...